Compare Moody's Corporation (MCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Viatris Inc — how do they compare? Moody's Corporation trades at $490.77 (market cap $88.28B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Moody's Corporation is far larger — about 4.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MCO | VTRS | |
|---|---|---|
Market Cap | $88.28B | $19.79B |
Sector | Financials | Health |
52-Week High | $539.61 | $17.39 |
52-Week Low | $412.23 | $8.74 |
Enterprise Value | $94.08B | $32.00B |
Dividend Yield | 0.82% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $490.54, down 3.97% in the last session, with strong fundamentals including 31.69% net income margin and 74.54% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, while recent earnings consistently beat expectations. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, with Q2 2026 results expected on July 22, 2026.
MCO presents a compelling investment case with premium valuation metrics (P/E 36.25) justified by exceptional profitability and market dominance. Key risks include valuation sensitivity and dependence on debt issuance cycles. Analyst consensus remains bullish with $558.14 price target, representing 13.8% upside potential from current levels.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
